1. Starting point: what CorMedix looks like today

CorMedix in early 2026 is very different from the small, single-asset story most investors remember from the pre-launch DefenCath days. The company now combines three pillars:

1.1. DefenCath – from launch to “real” business

DefenCath (taurolidine and heparin) is approved in the US for the prevention of catheter-related bloodstream infections in adult patients receiving chronic hemodialysis through a central venous catheter. The product is commercialized with TDAPA (Transitional Drug Add-On Payment Adjustment) support in the ESRD bundle, and has gradually moved from a theoretical opportunity to a tangible revenue driver with triple-digit year-on-year growth in 2024–2025, as highlighted in the company’s Q3 2025 results (CorMedix Q3 2025 release).

In that Q3 report, CorMedix disclosed net revenue of $104.3M (pro forma $130.8M including Melinta), with DefenCath contributing roughly $88.8M on a pro forma basis and driving a strong improvement in profitability and cash generation. The combination of growing DefenCath penetration, TDAPA economics and lean operating structure has pushed the business into a level of operating leverage that was simply not visible two years ago.

1.2. Melinta – from one product to a full anti-infective platform

The August 2025 acquisition of substantially all assets of Melinta Therapeutics added a portfolio of branded anti-infective products (MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA) and the cardiovascular product TOPROL-XL to the CorMedix platform. The transaction transformed CorMedix into a broader hospital and infectious-disease company, with multiple revenue streams and cross-selling potential across ID specialists and hospital systems (Willkie / Melinta deal summary).

While integration risk is always real, by Q3 2025 CorMedix was already reporting meaningful progress: net revenue more than doubled year on year, pro forma EBITDA guidance was raised to the $220–240M range for full-year 2025, and management highlighted that around $30M of the expected $35–45M Melinta cost synergies were already captured. In practice, the company has moved from burning cash to generating it, which matters a lot when we discuss buybacks and future R&D investments.

1.3. Where the numbers stand going into 2026

Entering 2026, CorMedix combines:

• a DefenCath business that is already an established product in the dialysis ecosystem, with TDAPA support and further label expansion opportunities for Total Parenteral Nutrition (TPN) and pediatric hemodialysis populations (ongoing clinical programs described in company materials and regulatory filings);
• a portfolio of marketed products from Melinta that should provide a relatively diversified revenue base versus a pure single-asset story;
• an advancing late-stage program for REZZAYO (rezafungin) in prophylaxis of invasive fungal disease in adult allogeneic blood and marrow transplant (BMT) patients, with topline data expected around Q2 2026 (Melinta / REZZAYO clinical trial overview);
• and a balance sheet that, according to the latest disclosures, now supports both pipeline progress and capital return.

2. Balance sheet, cash flow and the $75M buyback

2.1. From funding worries to cash generation

Looking back just a couple of years, a large part of the CRMD debate was about dilution risk, manufacturing setbacks and whether the company would ever reach a scale where DefenCath could support itself. The picture in late 2025 is very different. The Q3 2025 release showed:

• net revenue of $104.3M, or $130.8M on a pro forma basis including Melinta;
• net income of $108.6M, helped by non-cash items, but with clearly positive operating profitability;
• pro forma EBITDA guidance of $220–240M for full-year 2025;
• and cash and equivalents of $55.7M at September 30 2025, with management guiding to around $100M at year-end 2025.

By the time of the February 2 2026 share repurchase announcement, CorMedix reported approximately $150M in cash and cash equivalents and 79.3M common shares outstanding as of December 31 2025, underlining that the business has entered a phase of ongoing cash generation.

2.2. The $75M buyback – what it means in practice

On February 2 2026, CorMedix announced that its Board of Directors had authorized a share repurchase program of up to $75M, valid through December 31 2027. The company expects to begin repurchasing shares as early as Q1 2026, with the usual flexibility regarding pace and execution (open-market purchases, block trades, trading plans, etc.).

Importantly, management explicitly framed the buyback as a way to return capital while maintaining flexibility to invest in growth and potential inorganic opportunities. Coming from a company that not long ago was fighting to get its first product to market, that shift in language and capital allocation is itself a signal: CorMedix now sees itself as a cash generator, not just a “story stock” that needs the market’s patience.

For shareholders, the combination to watch is:

• organic growth from DefenCath and the Melinta portfolio;
• potential step-ups from label expansions and new indications (REZZAYO prophylaxis, DefenCath TPN/pediatric);
• and a shrinking share count if the buyback is executed consistently over the next two years.

It is also worth noting that a company with a history of dilution and manufacturing hiccups deciding to put a material amount of capital into repurchases sends a credibility message to both the market and to its own long-term retail base.

3. Kidney policy, TDAPA and the KCAPA legislative angle

3.1. TDAPA: today’s reality

DefenCath currently benefits from TDAPA, a mechanism that lets certain novel dialysis-related drugs receive additional reimbursement on top of the ESRD bundle for a limited transition period. This framework has been crucial in supporting early uptake and economics for DefenCath in the US dialysis market, especially as providers adapt protocols and build real-world experience with the product.

By design, however, TDAPA is temporary. Once the transition period ends, products are expected to be incorporated into the base rate, which always raises questions about what reimbursement will look like and whether providers will maintain or expand adoption under a different economic regime. This is not a CRMD-only issue; it’s a structural feature of how Medicare handles new technologies in ESRD.

3.2. KCAPA and the broader kidney policy discussion

In parallel with DefenCath’s commercial rollout, US kidney policy has been moving. Proposals such as the Kidney Care Access Protection Act (KCAPA; see for example the Senate summary of S.2730 / “Kidney Care Access Protection Act” ) aim to protect access to innovative therapies and ensure that reimbursement structures do not unintentionally push providers away from clinically valuable, infection-reducing options.

There is no guarantee that any single bill will pass exactly as written, and investors should be careful not to treat KCAPA or similar proposals as “done deals.” That said, the direction of travel in policy discussions – recognizing the cost and human impact of catheter-related infections and supporting preventive solutions – clearly aligns with the core value proposition of DefenCath.

For investors who followed the legislative angle closely, the January 12 legislative update on CRMD and KCAPA provided an early, detailed look at how this policy backdrop could influence the long-term DefenCath opportunity. This new deep dive takes that discussion a step further by adding the Melinta integration, the buyback and the updated 2026–2027 catalyst map.

3.3. What is realistic to expect?

A balanced view, in my opinion, is to treat TDAPA as a real but time-limited tailwind and KCAPA-type reforms as a potential, not a base-case certainty. If Congress ultimately enacts legislation that extends or reinforces reimbursement for high-value infection-prevention tools in dialysis, DefenCath stands to benefit disproportionately. If that process stalls or gets watered down, CorMedix will have to rely more on pure commercial execution and on the Melinta platform to sustain growth.

In both scenarios, execution on the basics – infection-reduction data, contracting, medical-affairs work and real-world outcomes – will matter more than headlines.

4. Pipeline & late-stage assets: DefenCath label expansion and REZZAYO

4.1. DefenCath beyond hemodialysis

While hemodialysis via central venous catheter is the core of DefenCath’s current label, CorMedix is running additional clinical studies to expand its use into:

• Total Parenteral Nutrition (TPN) populations, where catheter-related infections are also a major source of morbidity, cost and hospitalization;
• pediatric hemodialysis, an area of high unmet need where infection prevention options are limited and where the risk/benefit calculus is particularly sensitive.

These programs, as described in company pipeline updates and regulatory filings, may not have the same media visibility as DefenCath’s initial launch, but they are central to the long-term thesis: the more settings in which DefenCath can show clear infection-reduction benefits, the more defensible and durable the franchise becomes, regardless of the exact timing of TDAPA-related policy shifts.

4.2. REZZAYO prophylaxis trial – a 2026 binary but not “all-or-nothing”

REZZAYO (rezafungin) is already approved in the US for the treatment of candidemia and invasive candidiasis in adults, based on its Phase III data in treatment settings. The ongoing Phase III study in prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic blood and marrow transplant (BMT) is a different, higher-risk and higher-reward opportunity.

Topline results from this prophylaxis trial are expected around Q2 2026, according to company communications and Melinta’s clinical-trials information (Rezzayo clinical-trials overview). A positive read-out could expand REZZAYO’s use into a high-value transplant prophylaxis segment, adding a second strong leg to the Melinta portfolio inside CorMedix. A negative or inconclusive result would not destroy the existing treatment indication, but it would remove an important upside driver that some investors are clearly counting on.

In other words, REZZAYO prophylaxis is a meaningful binary event, but it sits on top of an already commercialized product and a broader portfolio. That helps the risk/reward profile compared to “single Phase 3 or bust” stories.

5. From single-asset to platform: Melinta integration and 2026–2027 trajectory

A key part of the bullish thesis on CRMD is that the company is no longer a mono-product vehicle that lives or dies purely on dialysis dynamics. The Melinta assets provide diversification across severe bacterial and fungal infections, hospital ID practice and even cardiology via TOPROL-XL. The Q3 2025 numbers suggest that the integration is not only progressing but also adding scale and operating leverage.

If CorMedix can maintain:

• mid-to-high-double-digit growth for DefenCath inside dialysis and, over time, TPN/pediatrics;
• a stable or gently growing revenue base across Melinta’s antibiotics and antifungal portfolio;
• and disciplined SG&A and R&D spending;

then the current guidance ranges for 2025 could become a stepping stone rather than a peak. That is where the $75M buyback becomes particularly interesting: in a scenario where free cash flow continues to grow, buybacks can be scaled up over time, not just executed once and forgotten.

On the other hand, investors should be honest about the risks: Melinta’s products live in a tough market (antibiotics and hospital antifungals are notoriously challenging businesses), pricing pressure is always a factor, and integration work can go off track if execution slips. The reward comes precisely from the combination of these risks with the upside from DefenCath, REZZAYO and the policy angle.

6. Sentiment, technical setup and the bounce from ~6.50

6.1. Short interest and analyst targets

On the sentiment side, CRMD still looks like a “battleground” name rather than a consensus long. Data from ShortSqueeze indicate around 16.7M shares sold short, with roughly 5–6 days to cover based on recent trading volumes ( ShortSqueeze CRMD overview ). That is elevated for a sub-$1B market-cap stock and creates the possibility of sharp moves when news flow surprises or liquidity dries up.

On the other side of the tape, a December 2025 piece from Zacks highlighted that the mean of Wall Street analysts’ price targets implied roughly 60–70% upside versus then-current levels (Zacks CRMD target-price article). Analysts can certainly be wrong, but the existence of such a spread between current price and target range shows that at least part of the sell-side sees DefenCath and the Melinta platform as under-appreciated.

6.2. The technical picture: spike, fade and bounce from mid-$6s

From a purely technical standpoint, the last few months have drawn a fairly classic pattern for a name that transitions from “hope” to “numbers.” The stock spiked on the back of strong 2025 guidance and Melinta integration, then faded as short-term traders took profits and macro conditions remained choppy. That fade took CRMD back into the mid-$6s (around 6.5 USD), an area that roughly coincides with a prior consolidation zone and, depending on the chart settings, with key moving averages.

The subsequent bounce – helped by updated fundamental data and, crucially, by the announcement of the $75M repurchase program – brought the stock back above prior resistance and, if sustained, may turn that $6.50 area into a reference support level. Technicians will want to watch the interplay between:

• the $6–7 zone as potential support;
• the high-$8s / low-$9s where sellers have previously appeared;
• and the evolution of volume on up-moves versus down-moves as the buyback starts to operate in Q1 2026.

It is essential to stress that technicals do not change the underlying clinical and policy risks; they simply describe how the market is digesting those fundamentals over time.

7. Risk map and what could break the bullish thesis

The key risks include:

• Reimbursement risk. TDAPA is temporary by design, and the details of how DefenCath is ultimately treated in the ESRD bundle will matter for long-term margins and incentives. Policy reforms like KCAPA may help, but they are not guaranteed.
• Execution & integration. Keeping DefenCath’s launch trajectory on track while integrating Melinta’s portfolio is operationally complex. Missteps in manufacturing, supply, contracting or hospital access could show up quickly in the P&L.
• Pipeline risk. REZZAYO’s prophylaxis trial is a real binary: failure would not destroy the current treatment indication, but it would heavily reduce the upper-end bull case around the product.
• Competition. Both dialysis infection-prevention and anti-infective hospital markets are competitive and exposed to generic pressure, stewardship programs and changing guidelines.
• Market & liquidity. A relatively high short interest and small/mid-cap status mean CRMD can remain volatile, with moves that occasionally disconnect from fundamentals in both directions.

8. Big picture: why CRMD still matters in 2026

Put simply, CRMD today is a company with:

• a real, growing product (DefenCath) addressing a real clinical and economic problem (catheter-related infections);
• a broader anti-infective platform via Melinta that diversifies revenue sources;
• a late-stage pipeline with visible 2026–2027 readouts that can expand the story further;
• a policy backdrop that, while uncertain, is clearly shifting in favor of better infection prevention in dialysis;
• a balance sheet strong enough to support both R&D and a meaningful buyback.

The February 2026 share repurchase authorization does not magically remove risk, but it crystallizes how far the story has come: instead of asking whether CorMedix will survive, the debate now is about how much value can be extracted from DefenCath, Melinta and REZZAYO, and how that value will be split between growth investments and returns of capital to shareholders.